SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases today announced it will be presenting five posters at the American Society of Nephrology’s Kidney Week 2020 virtual meeting to be held October 22-25, 2020.
All Angion’s posters will be available beginning Thursday, October 22nd at 10:00am EDT.
Title: Defining a Minimal Clinically Meaningful Difference (MCMD) in Estimated Glomerular Filtration Rate (eGFR) for Kidney Transplantation
Poster Number: PO2424
Session: Clinical and Immunologic Predictors of Post-Transplant Outcomes
Title: Design of the Graft Improvement Following Transplant (GIFT) trial, a phase 3 study of ANG-3777 in kidney transplantation patients with delayed graft function
Poster Number: PO2418
Session: Clinical and Immunologic Predictors of Post-Transplant Outcomes
Title: The Effect of ANG-3777 on The Growth of c-MET-Expressing Human Tumor Cells in Immunocompromised Mice
Poster Number: PO0249
Session: AKI Mechanisms - 3
Title: The Effect of ANG-3777 on In Vitro Cell Proliferation
Poster Number: PO0248
Session: AKI Mechanisms – 3
Title: Compartmental Differences within the COL3A1 Network in Proteinuric Kidney Disease; Informing Drug Activity Using the Jaccard-Tanimoto Index
Poster Number: PO1712
Session: Glomerular Diseases: Fibrosis and Extracellular Matrix
After the conclusion of the Kidney Week 2020 sessions, copies of each presentation will be also available in the “Publications” section of the Angion website.
About ANG-3777
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair. ANG-3777 has a substantially longer half-life than HGF and Angion believes ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia.
About Angion Biomedica Corp.
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach. For further information, please visit www.angion.com.
Contacts
Investor Contact
Daniel Ferry
LifeSci Advisors
617-535-7746
daniel@lifesciadvisors.com
Media Contact
Cherilyn Cecchini, M.D.
LifeSci Communications
646-876-5196
ccecchini@lifescicomms.com